清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

医学 美罗华 视神经脊髓炎 安慰剂 相伴的 泼尼松龙 内科学 扩大残疾状况量表 多发性硬化 临床试验 儿科 外科 免疫学 病理 淋巴瘤 替代医学
作者
Masayuki Tahara,Tomoko Oeda,Kazumasa Okada,Takao Kiriyama,Kazuhide Ochi,Hirofumi Maruyama,Hikoaki Fukaura,Kyoichi Nomura,Yuko Shimizu,Masahiro Mori,Ichiro Nakashima,Tatsuro Misu,Atsushi Umemura,Kenji Yamamoto,Hideyuki Sawada
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:19 (4): 298-306 被引量:385
标识
DOI:10.1016/s1474-4422(20)30066-1
摘要

Pharmacological prevention against relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) is developing rapidly. We aimed to investigate the safety and efficacy of rituximab, an anti-CD20 monoclonal antibody, against relapses in patients with NMOSD.We did a multicentre, randomised, double-blind, placebo-controlled clinical trial at eight hospitals in Japan. Patients aged 16-80 years with NMOSD who were seropositive for aquaporin 4 (AQP4) antibody, were taking 5-30 mg/day oral steroids, and had an Expanded Disability Status Scale (EDSS) score of 7·0 or less were eligible for the study. Individuals taking any other immunosuppressants were excluded. Participants were randomly allocated (1:1) either rituximab or placebo by a computer-aided dynamic random allocation system. The doses of concomitant steroid (converted to equivalent doses of prednisolone) and relapses in previous 2 years were set as stratification factors. Participants and those assessing outcomes were unaware of group assignments. Rituximab (375 mg/m2) was administered intravenously every week for 4 weeks, then 6-month interval dosing was done (1000 mg every 2 weeks, at 24 weeks and 48 weeks after randomisation). A matching placebo was administered intravenously. Concomitant oral prednisolone was gradually reduced to 2-5 mg/day, according to the protocol. The primary outcome was time to first relapse within 72 weeks. Relapses were defined as patient-reported symptoms or any new signs consistent with CNS lesions and attributable objective changes in MRI or visual evoked potential. The primary analysis was done in the full analysis set (all randomly assigned patients) and safety analyses were done in the safety analysis set (all patients who received at least one infusion of assigned treatment). The primary analysis was by intention-to-treat principles. This trial is registered with the UMIN clinical trial registry, UMIN000013453.Between May 10, 2014, and Aug 15, 2017, 38 participants were recruited and randomly allocated either rituximab (n=19) or placebo (n=19). Three (16%) patients assigned rituximab discontinued the study and were analysed as censored cases. Seven (37%) relapses occurred in patients allocated placebo and none were recorded in patients assigned rituximab (group difference 36·8%, 95% CI 12·3-65·5; log-rank p=0·0058). Eight serious adverse events were recorded, four events in three (16%) patients assigned rituximab (lumbar compression fracture and infection around nail of right foot [n=1], diplopia [n=1], and uterine cancer [n=1]) and four events in two (11%) people allocated to placebo (exacerbation of glaucoma and bleeding in the right eye chamber after surgery [n=1], and visual impairment and asymptomatic white matter brain lesion on MRI [n=1]); all patients recovered. No deaths were reported.Rituximab prevented relapses for 72 weeks in patients with NMOSD who were AQP4 antibody-positive. This study is limited by its small sample size and inclusion of participants with mild disease activity. However, our results suggest that rituximab could be useful maintenance therapy for individuals with NMOSD who are AQP4 antibody-positive.Japanese Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development, and Zenyaku Kogyo.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
快乐舒完成签到 ,获得积分10
18秒前
n01W97的应助被科研通管家采纳,获得40
36秒前
无限的水香完成签到,获得积分10
54秒前
朴实水云完成签到,获得积分10
55秒前
Cakoibao的应助被dianeil采纳,获得10
1分钟前
YYM完成签到 ,获得积分10
1分钟前
1分钟前
激情的盼晴完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
yanweihome完成签到 ,获得积分10
1分钟前
1分钟前
高高仰完成签到,获得积分10
2分钟前
2分钟前
缓慢忆灵完成签到,获得积分10
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
沉默的樱完成签到,获得积分10
2分钟前
五月完成签到,获得积分10
2分钟前
balko完成签到,获得积分10
2分钟前
高兴战斗机完成签到,获得积分10
2分钟前
3分钟前
suge完成签到,获得积分10
3分钟前
潇洒小海豚完成签到,获得积分10
3分钟前
笑点低的如萱完成签到,获得积分10
3分钟前
3分钟前
3分钟前
赖茜发布了新的文献求助10
3分钟前
xfy完成签到,获得积分10
4分钟前
务实的香薇完成签到,获得积分10
4分钟前
宝石完成签到,获得积分10
4分钟前
Maestro_S的应助被科研通管家采纳,获得20
4分钟前
4分钟前
4分钟前
复杂惜珊完成签到,获得积分10
4分钟前
u404711发布了新的文献求助10
4分钟前
激情的冰绿完成签到 ,获得积分10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185376
求助须知:如何正确求助?哪些是违规求助? 9574120
关于积分的说明 21834329
捐赠科研通 7782804
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558824
邀请新用户注册赠送积分活动 2481272